IGF1 and neoplasm: EC patients had higher serum IGF-1, lower tumor phospho-AMPK, and higher tumor phospho-mTOR at baseline than non-EC patientsMetformin led to lower serum IGF-1, higher tumor phospho-AMPK and lower tumor phospho-mTOR in EC patients